Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas

G. L. Shen, J. L. Li, M. A. Ghetie, V. Ghetie, R. D. May, M. Till, A. N. Brown, M. Relf, P. Knowles, J. W. Uhr, G. Janossy, P. Amlot, E. S. Vitetta, P. E. Thorpe

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Ricin A chain-containing immunotoxins (IT-As) specific for the human B-cell antigen, CD22, were prepared from 4 monoclonal antibodies (MAbs) or their Fab' fragments: RFB4, HD6, UV22-1 and UV22-2. The ITs were tested for their ability to kill cells from the Burkitt lymphoma line, Daudi, the pre-B-cell leukemia line, NALM-6, and the myeloma cell line, ARH-77. Daudi expresses high levels of CD22, whereas NALM-6 and ARH-77 express low levels of CD22. The IgG-RFB4-A was higly toxic to all 3 cell lines; it killed 50% of the Daudi cells at a concentration of 1.2 x 10-12 M and 50% of NALM-6 and ARH-77 cells at concentrations of 1.5 x 10-11 M. IgG-RFB4-A was 10-30 times more toxic to Daudi cells than were the IgG-As constructed from the other 3 CD22 MAbs and 10 times more toxic than ricin itself. IT-As constructed from the Fab' fragments of the 4 CD22 antibodies were 2 to 5 times less toxic to Daudi cells than their IgG-A counterparts. Fab'-RFB4-A was twice as toxic to Daudi cells as ricin, whereas the other Fab'-As were about 7 times less toxic than ricin. Scatchard analyses of the binding of the radio-iodinated antibodies to Daudi cells showed that the intact RFB4 antibody bound 3-10 times more strongly than the other antibodies, whereas the Fab'-RFB4 bound 1.2 to 3.5 times more strongly than the Fab' fragments prepared from the other antibodies. Thus, the potent cytotoxic activity of the RFB4-As appears to derive, in part, from their superior binding affinity. Prior studies have shown that UV22-1 and HD6 cross-react with certain normal human tissues lacking cells of B-cell lineage, whereas UV22-2 and RFB4 are B-cell-specific. This fact, together with its superior potency as an IT-A, suggests that RFB4 is the antibody of choice for preparing Fab'-As or IgG-As for in vivo therapy of human B-cell leukemias and lymphomas.

Original languageEnglish (US)
Pages (from-to)792-797
Number of pages6
JournalInternational Journal of Cancer
Volume42
Issue number5
StatePublished - 1988

Fingerprint

B-Cell Leukemia
Ricin
Immunotoxins
B-Cell Lymphoma
Poisons
Antibodies
Immunoglobulin G
Immunoglobulin Fab Fragments
B-Lymphocytes
Therapeutics
Cell Line
Sialic Acid Binding Ig-like Lectin 2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal Antibodies
Burkitt Lymphoma
Cell Lineage
Radio

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shen, G. L., Li, J. L., Ghetie, M. A., Ghetie, V., May, R. D., Till, M., ... Thorpe, P. E. (1988). Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. International Journal of Cancer, 42(5), 792-797.

Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. / Shen, G. L.; Li, J. L.; Ghetie, M. A.; Ghetie, V.; May, R. D.; Till, M.; Brown, A. N.; Relf, M.; Knowles, P.; Uhr, J. W.; Janossy, G.; Amlot, P.; Vitetta, E. S.; Thorpe, P. E.

In: International Journal of Cancer, Vol. 42, No. 5, 1988, p. 792-797.

Research output: Contribution to journalArticle

Shen, GL, Li, JL, Ghetie, MA, Ghetie, V, May, RD, Till, M, Brown, AN, Relf, M, Knowles, P, Uhr, JW, Janossy, G, Amlot, P, Vitetta, ES & Thorpe, PE 1988, 'Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas', International Journal of Cancer, vol. 42, no. 5, pp. 792-797.
Shen, G. L. ; Li, J. L. ; Ghetie, M. A. ; Ghetie, V. ; May, R. D. ; Till, M. ; Brown, A. N. ; Relf, M. ; Knowles, P. ; Uhr, J. W. ; Janossy, G. ; Amlot, P. ; Vitetta, E. S. ; Thorpe, P. E. / Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. In: International Journal of Cancer. 1988 ; Vol. 42, No. 5. pp. 792-797.
@article{7cfc416cbb4d4ced955fa0a93deebb49,
title = "Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas",
abstract = "Ricin A chain-containing immunotoxins (IT-As) specific for the human B-cell antigen, CD22, were prepared from 4 monoclonal antibodies (MAbs) or their Fab' fragments: RFB4, HD6, UV22-1 and UV22-2. The ITs were tested for their ability to kill cells from the Burkitt lymphoma line, Daudi, the pre-B-cell leukemia line, NALM-6, and the myeloma cell line, ARH-77. Daudi expresses high levels of CD22, whereas NALM-6 and ARH-77 express low levels of CD22. The IgG-RFB4-A was higly toxic to all 3 cell lines; it killed 50{\%} of the Daudi cells at a concentration of 1.2 x 10-12 M and 50{\%} of NALM-6 and ARH-77 cells at concentrations of 1.5 x 10-11 M. IgG-RFB4-A was 10-30 times more toxic to Daudi cells than were the IgG-As constructed from the other 3 CD22 MAbs and 10 times more toxic than ricin itself. IT-As constructed from the Fab' fragments of the 4 CD22 antibodies were 2 to 5 times less toxic to Daudi cells than their IgG-A counterparts. Fab'-RFB4-A was twice as toxic to Daudi cells as ricin, whereas the other Fab'-As were about 7 times less toxic than ricin. Scatchard analyses of the binding of the radio-iodinated antibodies to Daudi cells showed that the intact RFB4 antibody bound 3-10 times more strongly than the other antibodies, whereas the Fab'-RFB4 bound 1.2 to 3.5 times more strongly than the Fab' fragments prepared from the other antibodies. Thus, the potent cytotoxic activity of the RFB4-As appears to derive, in part, from their superior binding affinity. Prior studies have shown that UV22-1 and HD6 cross-react with certain normal human tissues lacking cells of B-cell lineage, whereas UV22-2 and RFB4 are B-cell-specific. This fact, together with its superior potency as an IT-A, suggests that RFB4 is the antibody of choice for preparing Fab'-As or IgG-As for in vivo therapy of human B-cell leukemias and lymphomas.",
author = "Shen, {G. L.} and Li, {J. L.} and Ghetie, {M. A.} and V. Ghetie and May, {R. D.} and M. Till and Brown, {A. N.} and M. Relf and P. Knowles and Uhr, {J. W.} and G. Janossy and P. Amlot and Vitetta, {E. S.} and Thorpe, {P. E.}",
year = "1988",
language = "English (US)",
volume = "42",
pages = "792--797",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas

AU - Shen, G. L.

AU - Li, J. L.

AU - Ghetie, M. A.

AU - Ghetie, V.

AU - May, R. D.

AU - Till, M.

AU - Brown, A. N.

AU - Relf, M.

AU - Knowles, P.

AU - Uhr, J. W.

AU - Janossy, G.

AU - Amlot, P.

AU - Vitetta, E. S.

AU - Thorpe, P. E.

PY - 1988

Y1 - 1988

N2 - Ricin A chain-containing immunotoxins (IT-As) specific for the human B-cell antigen, CD22, were prepared from 4 monoclonal antibodies (MAbs) or their Fab' fragments: RFB4, HD6, UV22-1 and UV22-2. The ITs were tested for their ability to kill cells from the Burkitt lymphoma line, Daudi, the pre-B-cell leukemia line, NALM-6, and the myeloma cell line, ARH-77. Daudi expresses high levels of CD22, whereas NALM-6 and ARH-77 express low levels of CD22. The IgG-RFB4-A was higly toxic to all 3 cell lines; it killed 50% of the Daudi cells at a concentration of 1.2 x 10-12 M and 50% of NALM-6 and ARH-77 cells at concentrations of 1.5 x 10-11 M. IgG-RFB4-A was 10-30 times more toxic to Daudi cells than were the IgG-As constructed from the other 3 CD22 MAbs and 10 times more toxic than ricin itself. IT-As constructed from the Fab' fragments of the 4 CD22 antibodies were 2 to 5 times less toxic to Daudi cells than their IgG-A counterparts. Fab'-RFB4-A was twice as toxic to Daudi cells as ricin, whereas the other Fab'-As were about 7 times less toxic than ricin. Scatchard analyses of the binding of the radio-iodinated antibodies to Daudi cells showed that the intact RFB4 antibody bound 3-10 times more strongly than the other antibodies, whereas the Fab'-RFB4 bound 1.2 to 3.5 times more strongly than the Fab' fragments prepared from the other antibodies. Thus, the potent cytotoxic activity of the RFB4-As appears to derive, in part, from their superior binding affinity. Prior studies have shown that UV22-1 and HD6 cross-react with certain normal human tissues lacking cells of B-cell lineage, whereas UV22-2 and RFB4 are B-cell-specific. This fact, together with its superior potency as an IT-A, suggests that RFB4 is the antibody of choice for preparing Fab'-As or IgG-As for in vivo therapy of human B-cell leukemias and lymphomas.

AB - Ricin A chain-containing immunotoxins (IT-As) specific for the human B-cell antigen, CD22, were prepared from 4 monoclonal antibodies (MAbs) or their Fab' fragments: RFB4, HD6, UV22-1 and UV22-2. The ITs were tested for their ability to kill cells from the Burkitt lymphoma line, Daudi, the pre-B-cell leukemia line, NALM-6, and the myeloma cell line, ARH-77. Daudi expresses high levels of CD22, whereas NALM-6 and ARH-77 express low levels of CD22. The IgG-RFB4-A was higly toxic to all 3 cell lines; it killed 50% of the Daudi cells at a concentration of 1.2 x 10-12 M and 50% of NALM-6 and ARH-77 cells at concentrations of 1.5 x 10-11 M. IgG-RFB4-A was 10-30 times more toxic to Daudi cells than were the IgG-As constructed from the other 3 CD22 MAbs and 10 times more toxic than ricin itself. IT-As constructed from the Fab' fragments of the 4 CD22 antibodies were 2 to 5 times less toxic to Daudi cells than their IgG-A counterparts. Fab'-RFB4-A was twice as toxic to Daudi cells as ricin, whereas the other Fab'-As were about 7 times less toxic than ricin. Scatchard analyses of the binding of the radio-iodinated antibodies to Daudi cells showed that the intact RFB4 antibody bound 3-10 times more strongly than the other antibodies, whereas the Fab'-RFB4 bound 1.2 to 3.5 times more strongly than the Fab' fragments prepared from the other antibodies. Thus, the potent cytotoxic activity of the RFB4-As appears to derive, in part, from their superior binding affinity. Prior studies have shown that UV22-1 and HD6 cross-react with certain normal human tissues lacking cells of B-cell lineage, whereas UV22-2 and RFB4 are B-cell-specific. This fact, together with its superior potency as an IT-A, suggests that RFB4 is the antibody of choice for preparing Fab'-As or IgG-As for in vivo therapy of human B-cell leukemias and lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=0024207837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024207837&partnerID=8YFLogxK

M3 - Article

C2 - 3263328

AN - SCOPUS:0024207837

VL - 42

SP - 792

EP - 797

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -